

Press Release

Lund, Sweden, December 19, 2024

ImmuneBiotech and Lund University Launch a Pioneering Clinical Study Linking Gut Health to Preeclampsia Prevention

ImmuneBiotech, a pioneering innovator in probiotic solutions, today announced a collaborative clinical study with researchers from Lund University and Region Skåne. The study aims to investigate whether restoring gut health through probiotics can help lower the risk of preeclampsia, a severe pregnancy complication affecting millions of women worldwide.

Preeclampsia, often referred to as pregnancy-induced hypertension, is one of the leading causes of maternal and fetal mortality globally. Marked by high blood pressure and associated complications, it can occur suddenly in seemingly healthy pregnancies, frequently requiring early delivery. Alarming, hypertensive disorders during pregnancy account for over 76,000 maternal deaths annually across the globe.

“Current treatment options for preeclampsia are very limited,” explains Professor Stefan Hansson of Lund University and Skåne University Hospital, the principal investigator of the study. “This clinical study offers the possibility of groundbreaking preventative strategies that could significantly improve care for expectant mothers worldwide.”

Recent research has highlighted the critical role of gut flora in overall health, with emerging evidence linking gut dysbiosis, inflammation, and intestinal barrier dysfunction to preeclampsia. A 2023 study*, conducted collaboratively by Professor Stefan Hansson’s research team and ImmuneBiotech, confirmed these connections, showing that pregnant women in Sweden with preeclampsia exhibited a significant imbalance in their gut microbiome compared to healthy pregnancies and frequently reported gut-related symptoms.

* [Gut Micro- and Mycobiota in Preeclampsia: Bacterial Composition Differences Suggest Role in Pathophysiology - PubMed](#)

Building on these findings, the new clinical trial, registered on ClinicalTrials.gov**, will explore whether restoring gut microbiome balance, strengthening the intestinal barrier, and suppressing inflammation through GutMagnific® - ImmuneBiotech’s scientifically designed probiotic blend - can help reduce the risk of this life-threatening condition. The study will include 150 pregnant women with risk, who will receive either GutMagnific® or a placebo, with researchers monitoring microbiomes, inflammation markers, and pregnancy outcomes.

** [Study Details | Probiotic Supplementation During Pregnancy in Women With High-Risk Pregnancies | ClinicalTrials.gov](#)

GutMagnific® contains five carefully selected strains of lactic acid bacteria, chosen for their ability to restore gut balance and reduce systemic inflammation, offering an innovative and natural approach to preeclampsia prevention. This research represents a significant step toward improving maternal health outcomes through precision probiotics.

“Gut health is increasingly recognized as a cornerstone of overall well-being,” says Dr. Shahram Lavasani, CEO of ImmuneBiotech. “We are excited to investigate the potential of GutMagnific® as a preventative solution for preeclampsia, providing

expectant mothers with a safe, natural, and scientifically grounded approach to supporting a healthy pregnancy.”

This announcement aligns with the mission of this year’s *Musikhjälpen*, Sweden’s nationwide charity event. The 2024 campaign focused on *Women’s Right to Survive Pregnancy*, a cause that deeply resonates with ImmuneBiotech’s commitment to advancing global health.

Dr. Lavasani adds, “Through innovative solutions like GutMagnific® and rigorous research, we aim to contribute to a future where every woman has access to the care and resources needed for a healthy pregnancy and a safe delivery.”

ImmuneBiotech extends its gratitude to Professor Stefan Hansson and his team for their invaluable collaboration in this groundbreaking study. Together, we have the opportunity to make a profound impact on the lives of countless women worldwide.

Lund University’s News on the Clinical Study of Probiotics and Preeclampsia:
[Kan probiotika göra skillnad för gravida med ökad risk för preeklampsi? | Medicinska fakulteten](#)

About ImmuneBiotech AB

ImmuneBiotech Medical Sweden AB stands at the forefront of the probiotics and microbiome industry, dedicated to transforming human health through cutting-edge, science-backed solutions. The company specializes in developing and marketing precision-engineered probiotic products that target critical health challenges, with a focus on gastrointestinal and neurological conditions.

With over two decades of pioneering research, ImmuneBiotech has unlocked groundbreaking insights into the complex relationship between the gut microbiome, immune system, and intestinal barrier. This expertise has culminated in the creation of *ImmuneBiotics*®, a revolutionary category of probiotics designed to deliver targeted, multi-faceted health benefits.

Driven by a passion for innovation, ImmuneBiotech combines rigorous scientific research with a customer-first approach to set new standards in the rapidly advancing probiotics field. As a leader in microbiome-based health solutions, the company is committed to addressing global health challenges and shaping the future of wellbeing.

GutMagnific®: Transforming Human Health with Precision Probiotics

GutMagnific® is ImmuneBiotech’s flagship product and a shining example of the power of Precision Probiotics. Designed for the effective management of gastrointestinal conditions, this scientifically developed, multi-strain, patented probiotic food/nutritional supplement goes beyond basic gut health. It works to restore balance across the gut microbiome, strengthen the intestinal barrier, and modulate the immune system.

What sets GutMagnific® apart is its broad-reaching impact. While it delivers remarkable results for gastrointestinal wellness, its benefits extend to addressing neurological conditions through the gut-brain axis. In a rigorous randomized, double-blind, placebo-controlled clinical trial conducted in collaboration with the Karolinska Institute in Stockholm, Sweden, GutMagnific demonstrated significant relief of both neurological and IBS symptoms in patients with myalgic encephalomyelitis (ME), commonly known as chronic fatigue syndrome (CFS).



GutMagnific[®] also holds promise for addressing a wide range of conditions with critical unmet medical needs, including constipation, abdominal pain, antibiotic-induced diarrhea, *Clostridium difficile* infection, leaky gut, and small intestinal bacterial overgrowth (SIBO).

The product reflects ImmuneBiotech's robust R&D platform, which applies pharmaceutical-grade precision to achieve multi-targeted therapeutic effects. By bridging cutting-edge science with practical health solutions, GutMagnific[®] represents a transformative step forward in human health and redefines what is possible with probiotics.

Learn more and purchase GutMagnific[®] at www.GutMagnific.com.

For further information, please contact:

Shahram Lavasani, CEO

ImmuneBiotech Medical Sweden AB

s.lavasani@immunebiotech.com

+46 700 90 8946

www.ImmuneBiotech.com